Matthew J. Wong

Ponatinib (AP24534), a Multitargeted Pan-FGFR Inhibitor with Activity in Multiple FGFR-Amplified or Mutated Cancer Models

Joseph M. Gozgit, Matthew J. Wong, Lauren Moran et al. · Molecular Cancer Therapeutics · 2012 · 317 citations · Full text

Activating alleles of JAK3 in acute megakaryoblastic leukemia

Denise K. Walters, Thomas Mercher, Ting-Lei Gu et al. · Cancer Cell · 2006 · 313 citations

Hematological Malignancy, Mixed-phenotype Acute Leukemia, Genetics +5

Potent Activity of Ponatinib (AP24534) in Models of FLT3-Driven Acute Myeloid Leukemia and Other Hematologic Malignancies

Joseph M. Gozgit, Matthew J. Wong, Scott Wardwell et al. · Molecular Cancer Therapeutics · 2011 · 151 citations · Full text

Hematological Malignancy, Vitro Inhibitory Activity, Mutant Bcr-abl +15

SGX393 inhibits the CML mutant Bcr-Abl ^T315I and preempts <i>in vitro</i> resistance when combined with nilotinib or dasatinib

Thomas O’Hare, Christopher A. Eide, Jeffrey Tyner et al. · Proceedings of the National Academy of Sciences · 2008 · 79 citations · Full text

Mutations of the BCR-ABL-kinase domain occur in a minority of patients with stable complete cytogenetic response to imatinib

Daniel W. Sherbenou, Matthew J. Wong, Adil Humayun et al. · Leukemia · 2007 · 77 citations

Hematological Malignancy, Medicine, Genetics +5